Browse the corpus

Betaxolol is an FDA-approved medication with applications in open-angle glaucoma, essential hypertension, post-myocardial infarction, and chronic stable angina. Classified as a selective β-1 adrenergic blocker, betaxolol distinguishes itself through ophthalmic and oral formulations tailored for specific therapeutic purposes. This course explores betaxolol, emphasizing its indications, mechanism of action, and contraindications, particularly for open-angle glaucoma and essential hypertension. Through an in-depth review of current literature, healthcare professionals will gain a thorough understanding of betaxol's pharmacology and clinical efficacy, enabling them to make informed decisions and effective interventions for optimal patient outcomes. Additionally, this curse explores off-label uses, dosing strategies, monitoring protocols, clinical toxicology considerations, and relevant drug interactions. By providing healthcare professionals with this essential knowledge, this educational initiative empowers them to address glaucoma and essential hypertension with betaxolol pharmacotherapy adeptly. Through a robust examination of the medication's intricacies, participants will be well-equipped to navigate the complexities of betaxolol administration, ensuring that patients receive optimal care and benefit from this versatile therapeutic option. Objectives: Identify the mechanism of action of betaxolol. Assess the adverse drug reactions of betaxolol. Implement the appropriate monitoring strategies for patients receiving betaxolol. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from betaxolol pharmacotherapy. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose The hallmarks of β-blocker toxicity include hypotension and bradycardia. What separates these clinical signs from other antihypertensives like calcium channel blockers is the presence of concurrent hyperkalemia and hypokalemia. Additionally, CNS depression, altered mental status, decreased myocardial contractility, arrhythmia, and respiratory compromise may be observed.[39][40] Management of Overdose As explained above, life-threatening symptoms may be observed; the first step in evaluating a patient with potential beta-blocker toxicity should be to address a patient's airway if needed. Atropine administration before intubation may be necessary to prevent the vagal parasympathetic response, which could exacerbate bradycardia. Magnesium sulfate and sodium bicarbonate are options for patients who develop QT prolongation. Glucagon and intravenous fluids are the first-line treatments of choice for hypotension and bradycardia and reversal of β-blocker toxicity. If the patient presents within 2 hours of ingestion, charcoal can help prevent the β-blocker's absorption from the gut. Gastric decontamination with lavage is also an option, albeit rarely used, for patients who ingested large amounts of the β-blockers or have severe symptoms.[41] Recommendations Although betaxolol is a selective β-1 receptor antagonist, its overdose symptoms are similar to the other β-blockers, including the nonselective agents. This similarity is because betaxolol loses its selectivity at higher therapeutic levels and begins to bind to β-2 and β-3 receptors.[3][42] The overdose of β-blockers has links with depression. Two-thirds of people who overdosed on β-blockers were taking a medication that was not prescribed for them.[39] Extracorporeal circulatory support may be necessary for a life-threatening overdose of betaxolol.[43]

Although it is not the first-line agent in the treatment of open-angle glaucoma, topical betaxolol is a valuable topical medication in the field of ophthalmology. Comprehensive knowledge of indications, contraindications, and adverse effects, as well as the monitoring of betaxolol pharmacotherapy, is essential for all interprofessional healthcare team members. Any deviations or adverse events should be reported to the ophthalmologist. A pharmacist serves as the bridge between the ophthalmologist and the primary care clinician caring for the patient. The pharmacist can recommend medical reconciliation to help ensure the safe treatment of a patient's ocular hypertension or open-angle glaucoma without affecting the treatment of a patient's other potential comorbidities. The pharmacist can also help educate nurses, clinician assistants, and clinicians not specializing in ophthalmology on administration, dosage, and possible adverse effects. An emergency room clinician should understand that betaxolol is a β-blocker and should be able to assess for β-blocker-related adverse effects, toxicity, and effective management. The primary care clinician should be aware of the patient's use of topical betaxolol and consider its potential adverse effects. A systematic review explored modifiable factors influencing glaucoma medication adherence from patient and healthcare professional viewpoints. The results underscored the necessity for collaborative efforts between healthcare providers like pharmacists, ophthalmologists, general practitioners, and patients to improve adherence. The key suggestions involved treatment regimen selection, enhancing glaucoma awareness, and fostering stronger patient-healthcare professional relationships. The research stressed the critical role of coordination between healthcare practitioners and patients in effectively addressing adherence concerns in glaucoma.[44]

A systematic review explored modifiable factors influencing glaucoma medication adherence from patient and healthcare professional viewpoints. The results underscored the necessity for collaborative efforts between healthcare providers like pharmacists, ophthalmologists, general practitioners, and patients to improve adherence. The key suggestions involved treatment regimen selection, enhancing glaucoma awareness, and fostering stronger patient-healthcare professional relationships. The research stressed the critical role of coordination between healthcare practitioners and patients in effectively addressing adherence concerns in glaucoma.[44] Although betaxolol is usually a tolerable and safe medication, it still has contraindications, adverse effects, and the potential for lethal toxicity. Every healthcare professional in the interprofessional team must comprehend their role and work together as a unit to ensure maximum safety and effectiveness of the treatment. Effective patient outcomes with betaxolol necessitate open communication and an interprofessional team approach involving clinicians, ophthalmologists, optometrists, and pharmacists.